Compare ELTK & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTK | IMMP |
|---|---|---|
| Founded | 1970 | 1987 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 54.4M |
| IPO Year | 1998 | 2012 |
| Metric | ELTK | IMMP |
|---|---|---|
| Price | $9.45 | $0.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 9.7K | ★ 605.0K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.18 | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.30 | $0.29 |
| 52 Week High | $12.19 | $3.53 |
| Indicator | ELTK | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 38.68 |
| Support Level | $8.05 | $0.35 |
| Resistance Level | $11.52 | $0.39 |
| Average True Range (ATR) | 0.66 | 0.02 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 32.62 | 29.98 |
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. The company manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. The geographic areas of the company are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.